SCHEMBL6167578

SCHEMBL6167578

Cc1c(Sc2ccc(Cl)nn2)oc2ccc(Cl)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.43
KCNH2 Q12809 1/20 0.40
AKR1B1 P15121 1/20 0.39
AHR P35869 6/20 0.36
ADORA3 P0DMS8 1/20 0.36
KMT2A Q03164 3/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 1/20 0.35
GPR55 Q9Y2T6 1/20 0.35
ADCY1 Q08828 1/20 0.35
RAB9A P51151 3/20 0.34
RXFP1 Q9HBX9 2/20 0.33
MEN1 O00255 2/20 0.33
NPC1 O15118 2/20 0.33
PKM P14618 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
MAOB P27338 2/20 0.32
KDM4E B2RXH2 1/20 0.32
CASP3 P42574 1/20 0.32
SENP8 Q96LD8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6176631 0.87 MCL1 (0.44) MCL1KCNH2AKR1B1AHRADORA3
SCHEMBL4453848 0.86 MCL1 (0.40) MCL1KCNH2AKR1B1AHRADORA3
SCHEMBL4449406 0.82 MCL1 (0.41) MCL1KCNH2AKR1B1AHRADORA3
SCHEMBL4462839 0.77 AKR1B1 (0.60) MCL1KCNH2AKR1B1ADORA3KMT2A
SCHEMBL5263709 0.70 AKR1B1 (0.40) KCNH2AKR1B1AHRKMT2AALDH1A1
SCHEMBL14409919 0.67 MCL1 (0.59) MCL1KCNH2AKR1B1AHRADORA3
SCHEMBL25824628 0.65 MCL1 (0.56) MCL1KCNH2AKR1B1AHRADORA3
SCHEMBL4449382 0.65 MCL1 (0.56) MCL1KCNH2AKR1B1AHRADORA3
SCHEMBL12248491 0.62 MCL1 (0.53) MCL1KCNH2AKR1B1AHRADORA3
SCHEMBL3684433 0.62 MCL1 (0.56) MCL1KCNH2AKR1B1AHRADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1463725-B1 PROCESS AND INTERMEDIATES FOR PYRIDAZINONE ANTIDIABETIC AGENTS PFIZER PROD INC (US) 2005-08-17 EP disclosed
EP-1463725-A1 PROCESS AND INTERMEDIATES FOR PYRIDAZINONE ANTIDIABETIC AGENTS Pfizer Products Inc. (US) 2004-10-06 EP disclosed
US-6759534-B2 REACTING BENZOFURAN DERIVATIVE WITH ORGANOLITHIUM COMPOUND IN PRESENCE OF SULFUR SOURCE; REACTING WITH DICHLOROPYRIDAZINE DERIVATIVE, REACTING WITH ALKALINE ALKOXIDE IN ALKANOL; REACTING WITH MINERAL ACID, OXIDATION PFIZER INC. 2004-07-06 US disclosed
US-20030162969-A1 Process and intermediates for pyridazinone antidiabetic agents TOM NORMA J (US) 2003-08-28 US disclosed
WO-2003057691-A1 PROCESS AND INTERMEDIATES FOR PYRIDAZINONE ANTIDIABETIC AGENTS PFIZER PRODUCTS INC. (US) 2003-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162969-A1 Process and intermediates for pyridazinone antidiabetic agents ALDOA, AKR1B1, DPYD MCL1 4399/4885KCNH2 835/4885AKR1B1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.